
Hints of moderation emerge in biotech venture funding
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.

A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.